- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
Risk of hospitalization or death from myocarditis, pericarditis and cardiac arrhythmia associated with SARS-CoV-2 is substantially higher than the same risk following vaccination with AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna vaccines. These findings were published in a study in Nature Medicine. The largest study yet "to compare the risk of cardiac events between different vaccine products and SARS-CoV2 infection" found that -
"First, there was an increase in the risk of myocarditis within a week of receiving the first dose of both adenovirus (AstraZeneca/Oxford) and mRNA (Pfizer/BioNTech, Moderna) vaccines, and a higher increased risk after the second dose of both mRNA vaccines. In contrast, we found no evidence of an increase in the risk of pericarditis or cardiac arrhythmias following vaccination, except in the 1–28 days following a second dose of the mRNA-1273 (Moderna) vaccine.
Second, in the same population, there was a greater risk of myocarditis, pericarditis and cardiac arrhythmia following SARS-CoV-2 infection.
Third, the increased risk of myocarditis after vaccination was higher in persons aged under 40 years."
Additional data provided by
English
Japanese
